Similarly, Shingrix will be a major growth driver for ... As for the legal risks, I believe these are ultimately the cost of doing business in healthcare, so it’s not an inherent risk for ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies third quarter 2024 financial results conference call.

Investing.com -- Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming ...

Choose wisely, experts say, when you pick your Medicare Part D prescription drug plan for 2025. What's in the formulary ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

Total revenues came in at £6.9 billion ($8.3 billion) – ahead of forecasts – although costs associated with ... quarter for our shingles vaccine Shingrix." Sales of the vaccine more than ...

The DMO has a huge mountain to climb and it will not be a cost-free enterprise for the economy ... Arexvy and its blockbuster shingles shot Shingrix are a big presence. But despite all the ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...

Shingrix was dubbed the "crown jewel" of ... The two companies said they will share development costs, with Pfizer claiming commercial rights to the shingles shot in all territories other than ...

Unknown litigation costs have cast a cloud over wide-moat ... GSK’s largest product, shingles vaccine Shingrix, does represent close to 10% of total sales, but we don’t expect heavy generic ...

It made recommended vaccines, such as Shingrix to prevent shingles ... you will have to pay the full cost of that drug. The $2,000 out-of-pocket cap won't apply. It's essential to carefully ...